source
- FDA Approves New Indication for Tzield (teplizumab) for Certain Pediatric Patients with Recently Diagnosed Stage 3 Type 1 DiabetesOn June 12, 2026, the U.S. Food and Drug Administration granted accelerated approval to Tzield (teplizumab) for a new indication, to delay the decline of insulin production in pediatric patients ag…fda press · 1mo ago↗ source
- Medicare drug price rule may target under-the-skin Keytruda and OpdivoFor 2029, a federal rule proposes closing a "loophole" that protects medicines transitioning from intravenous administration from price protection.BioPharma Dive · 1mo ago↗ source
- Lilly scores early positive data for new JAK drugAcquired through its purchase of Ajax, the drug showed encouraging effects in patients with hard-to-treat myelofibrosis. To analysts, such results could lead to competition for Incyte’s Jakafi.